ABBVIE INC

ABBVIE INC is a pharmaceutical manufacturer specializing in the research, development, and production of biologics and specialty pharmaceuticals for chronic and complex disease states. Core capabilities include advanced bioprocessing, aseptic manufacturing, formulation science, and regulatory-compliant production of monoclonal antibodies, immunotherapies, and small-molecule therapeutics. The company leverages GMP-compliant facilities with automated filling lines, process analytical technology (PAT), and real-time release testing to ensure product consistency and patient safety. Technical expertise spans cell line development, upstream/downstream purification, lyophilization, and cold chain logistics, with a focus on meeting FDA and international regulatory standards for biopharmaceutical manufacturing. ABBVIE’s differentiation lies in its integrated end-to-end drug development and commercial-scale production infrastructure, enabling rapid transition from clinical batches to high-volume commercial supply. Award history is not available to determine specific agency engagements or contract patterns. Consequently, no definitive agency relationships can be inferred from the provided data. The primary NAICS code 325414 reflects pharmaceutical preparation manufacturing, indicating direct involvement in the production of finished dosage forms for human use, including injectables, oral solids, and specialty formulations. This positions ABBVIE within the biopharmaceutical supply chain supporting federal health programs, though no specific vertical specializations can be confirmed from available award data. ABBVIE INC is a large, vertically integrated enterprise structured as a 2L entity, headquartered in North Chicago, Illinois. The company operates under stringent FDA and EMA regulatory frameworks but holds no active government certifications such as 8(a), HUBZone, or SDVOSB. Its physical and operational footprint is centered on its North Chicago manufacturing campus, with global distribution capabilities supporting both domestic and international markets. ABBVIE’s government market presence is inferred solely through its role as a supplier of regulated pharmaceutical products, with no public contract data available to characterize procurement relationships.